First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

The Lancet, 2021

Memorial Sloan Kettering Cancer Center, Cornell University, National Cancer Center Hospital East, Johannes Gutenberg University Mainz, Fundación Arturo López Pérez, Peking University, Peking University Cancer Hospital, Centrum Onkologii, Japanese Foundation For Cancer Research, Medical University of Lublin, Hospital de Câncer de Barretos, Zhongshan Hospital, The First Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen University, Fudan University, Universidad de La Frontera, Centre Hospitalier de l’Université de Montréal, National and Kapodistrian University of Athens, Laiko General Hospital of Athens, Instituto Nacional de Cancerología, University Hospital Cologne, Hospital Universitario Miguel Servet, National Institute of Oncology, St John of God Murdoch Hospital, Dana-Farber Cancer Institute, Bristol-Myers Squibb (United States), The University of Texas MD Anderson Cancer Center

View Free PDF Publisher Website

An abstract is not available for this record. Please visit the publisher website for more details.

2803

Citations